Patent · US Active

Internalizing human monoclonal antibodies targeting prostate cancer cells in situ

US8865873B2 · kind B2 · utility

19Cited by

2References

9Claims

0Family size

Assignee

The Regents of the University of California · US

Inventors

Bin Liu · Fishers, US
James D. Marks · Kensington, US

Key dates

Filing date	Mar 15, 2010
Grant date	Oct 21, 2014
Priority date	—
Expiry date	Jul 18, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/77
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

This invention provides a method that allows selection of antibodies against cells (e.g., tumor cells) in situ using laser capture microdissection. By restricting antibody selection to binders of internalizing epitopes, a panel of phage antibodies was generated that targets clinically represented prostate cancer antigens.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.